Gros David-Alexandre C 4
4 · Eledon Pharmaceuticals, Inc. · Filed Feb 2, 2023
Insider Transaction Report
Form 4
Gros David-Alexandre C
DirectorChief Executive Officer
Transactions
- Award
Stock Option (right to buy)
2023-02-01+300,000→ 300,000 totalExercise: $3.08Exp: 2033-02-01→ Common Stock (300,000 underlying) - Award
Stock Option (right to buy)
2023-02-01+153,600→ 153,600 totalExercise: $3.97Exp: 2032-02-01→ Common Stock (153,600 underlying)
Footnotes (2)
- [F1]This option represents a right to purchase up to 300,000 shares of Common Stock, which options vests with respect to 75,000 shares on February 1, 2024, and then with respect to 6.25% of the underlying shares quarterly over the three year period ending February 1, 2027.
- [F2]This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on February 1, 2022. The option satisfied the performance criteria with respect to 153,600 shares of underlying Common Stock and these credited shares will satisfy the time-based vesting criteria with respect to 38,400 shares of Common Stock on February 1, 2023, and then with respect to 1/48th of the credited shares monthly over the three-year period ending February 1, 2026.